U.S. Markets
FDA advisory committee recommends to widen access to BPC-157 peptide
StockNow breaking-news AI analysis
The FDA advisory committee recommended widening BPC-157 access, potentially allowing legal compounding. This contrasts with previous safety warnings but offers significant long-term growth opportunities for Hims & Hers Health.
What do investors think?
Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactionsStockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.